1312809-89-4

Upstream product

• 86404-63-9 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazolyl)ethanone 
• 100-01-6 4-nitro-aniline 
• 51336-94-8 2-chloro-1-(2,4-dichlorophenyl)ethanone 
• 372-18-9 1,3-Difluorobenzene 
• 278783-69-0 4-(4-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 86386-77-8 1-[2-(2,4-difluorophenyl)-2,3-epoxypropyl]-1H-1,2,4-triazole methanesulfonate 

Downstream Products

• 1312809-95-2 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)acetamide 
• 1312809-96-3 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)propionamide 
• 1312809-97-4 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)butyramide 
• 1312809-98-5 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)pentanamide 
• 1312809-99-6 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)hexanamide 
• 1312810-00-6 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)heptanamide 
• 1312810-01-7 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)octanamide 
• 1312810-02-8 2-cyano-N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)acetamide 
• 1312810-03-9 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)cyclopropanecarboxamide 
• 1312810-04-0 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)cyclohexanecarboxamide 
• 1312810-05-1 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)nicotinamide 
• 1312810-06-2 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)picolinamide 
• 1312810-07-3 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)furan-2-carboxamide 
• 1312810-08-4 N-(4-(1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-5-oxo-1H-1,2,4-triazol-4(5H)-yl)phenyl)thiophene-2-carboxamide 

Relevant academic research and scientific papers

Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one

Based on the structure of the active site of cytochrome P450 14α-demethylase (CYP51) and the conclusions of the structure-activity relationships of azole antifungals, a series of 1-(2-(2,4-difluoro-phenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one of fluconazole analogs was synthesized. All compounds were characterized by IR, HRMS, 1HNMR and 13C NMR spectroscopic analysis. Results of preliminary antifungal in vitro test using eight human pathogenic species showed that some compounds displayed comparable or even better antifungal activities than reference drug fluconazole and that compound 3i exhibited significant activity against Candida albicans being worthy of further optimization.

Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents

On the basis of the active site of lanosterol 14α-demethylase from Candida albicans (CACYP51), a series of 1-(2-(2,4-difluorophenyl)-2-hydroxy-3- (1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one derivatives were synthesized as fluconazole analogs. Results of the preliminary antifungal tests against eight human pathogenic fungi in vitro showed that these compounds exhibited activities to some extent, and some displayed excellent antifungal activities against C. albicans than reference drug fluconazole. Flexible molecular docking was used to analyze the structure-activity relationships (SARs) of the target compounds. The designed compounds interact with CACYP51 through hydrophobic, van der Waals and hydrogen-bonding interactions.